Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab

Recent studies in RAS wild-type (WT) metastatic colorectal cancer (mCRC) suggest that the survival benefits of therapy using anti-epidermal growth factor receptor (anti-EGFR) and anti-vascular endothelial growth factor (anti-VEGF) antibodies combined with chemotherapy are maximized when the anti-EGF...

詳細記述

保存先:
書誌詳細
出版年:Neoplasia
主要な著者: Taniguchi, Hiroya, Baba, Yuji, Sagiya, Yoji, Gotou, Masamitsu, Nakamura, Kazuhide, Sawada, Hiroshi, Yamanaka, Kazunori, Sakakibara, Yukiko, Mori, Ikuo, Hikichi, Yukiko, Soeda, Junpei, Baba, Hideo
フォーマット: Artigo
言語:Inglês
出版事項: Neoplasia Press 2018
主題:
Original article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6030230/
https://ncbi.nlm.nih.gov/pubmed/29802988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2018.04.006
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料